JP2015187119A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015187119A5 JP2015187119A5 JP2015096792A JP2015096792A JP2015187119A5 JP 2015187119 A5 JP2015187119 A5 JP 2015187119A5 JP 2015096792 A JP2015096792 A JP 2015096792A JP 2015096792 A JP2015096792 A JP 2015096792A JP 2015187119 A5 JP2015187119 A5 JP 2015187119A5
- Authority
- JP
- Japan
- Prior art keywords
- vegf
- expression
- formulation
- vegfr
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 25
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 25
- 238000009472 formulation Methods 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 18
- 230000000694 effects Effects 0.000 claims 14
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 12
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 12
- 108020004707 nucleic acids Proteins 0.000 claims 12
- 102000039446 nucleic acids Human genes 0.000 claims 12
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 8
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 8
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims 8
- 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 7
- 229940123429 VEGFR tyrosine kinase inhibitor Drugs 0.000 claims 4
- -1 VEGFR-2 nucleic acid Chemical class 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 3
- 108091008605 VEGF receptors Proteins 0.000 claims 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 239000000443 aerosol Substances 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000003906 humectant Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000002453 shampoo Substances 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 239000000344 soap Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000000475 sunscreen effect Effects 0.000 claims 2
- 239000000516 sunscreening agent Substances 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000002304 perfume Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76032806P | 2006-01-18 | 2006-01-18 | |
| US60/760,328 | 2006-01-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551385A Division JP2009523807A (ja) | 2006-01-18 | 2007-01-18 | リンパ機能を高める方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015187119A JP2015187119A (ja) | 2015-10-29 |
| JP2015187119A5 true JP2015187119A5 (https=) | 2016-04-14 |
Family
ID=38191298
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551385A Pending JP2009523807A (ja) | 2006-01-18 | 2007-01-18 | リンパ機能を高める方法 |
| JP2015096792A Pending JP2015187119A (ja) | 2006-01-18 | 2015-05-11 | リンパ機能を高める方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551385A Pending JP2009523807A (ja) | 2006-01-18 | 2007-01-18 | リンパ機能を高める方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8367609B2 (https=) |
| EP (2) | EP2272497B1 (https=) |
| JP (2) | JP2009523807A (https=) |
| KR (2) | KR20080087164A (https=) |
| CN (2) | CN103638522A (https=) |
| AT (1) | ATE476986T1 (https=) |
| DE (1) | DE602007008365D1 (https=) |
| ES (2) | ES2350269T3 (https=) |
| TW (1) | TWI428143B (https=) |
| WO (1) | WO2007084599A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080260861A1 (en) * | 2004-04-07 | 2008-10-23 | The General Hospital Corporation | Modulating Lymphatic Function |
| EP1922095A2 (en) | 2005-09-07 | 2008-05-21 | Tyco Healthcare Group LP | Wound dressing with vacuum reservoir |
| US8580755B2 (en) * | 2008-02-19 | 2013-11-12 | University Of Rochester | Methods and compositions for treating inflammatory conditions |
| US20140024025A1 (en) * | 2010-03-01 | 2014-01-23 | Andrew Harbottle | Uv associated mtdna fusion transcripts and methods and uses thereof |
| US10405961B2 (en) | 2013-03-14 | 2019-09-10 | Cell and Molecular Tissue Engineering, LLC | Coated surgical mesh, and corresponding systems and methods |
| US10130288B2 (en) | 2013-03-14 | 2018-11-20 | Cell and Molecular Tissue Engineering, LLC | Coated sensors, and corresponding systems and methods |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8821A (en) * | 1852-03-23 | Machiheiiy toe | ||
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6824777B1 (en) * | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| DE69419721T2 (de) | 1993-01-12 | 2000-04-27 | Biogen, Inc. | Rekombinante anti-vla4 antikörpermoleküle |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| GB9410533D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | In situ hybridisation and immuno-Chemical localisation of a growth factor |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6018098A (en) * | 1995-06-16 | 2000-01-25 | Thomas Jefferson University | In vivo and in vitro model of cutaneous photoaging |
| US7423125B2 (en) * | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6361946B1 (en) * | 1997-02-05 | 2002-03-26 | Licentia Ltd | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US20030143204A1 (en) | 2001-07-27 | 2003-07-31 | Lewis David L. | Inhibition of RNA function by delivery of inhibitors to animal cells |
| EP1283268A3 (en) | 1996-08-23 | 2004-01-02 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor D (VEGF-D) |
| FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
| US6337320B1 (en) * | 1996-10-11 | 2002-01-08 | Thione International, Inc. | Reparatives for ultraviolet radiation skin damage |
| KR100695590B1 (ko) * | 1996-11-01 | 2007-03-14 | 아크 테라퓨틱스 리미티드 | 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| US6093740A (en) * | 1997-04-30 | 2000-07-25 | Eli Lilly And Company | Therapeutic treatment for skin disorders |
| WO2000036421A1 (en) * | 1998-12-11 | 2000-06-22 | Eisai Co., Ltd. | Use of vascular endothelial growth factor (vegf) |
| WO2000037025A2 (en) * | 1998-12-21 | 2000-06-29 | Ludwig Institute For Cancer Research | Antibodies to truncated vegf-d and uses thereof |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| HK1042052A1 (zh) * | 1999-02-08 | 2002-08-02 | Human Genome Sciences, Inc. | 内皮血管生长因子-2 |
| WO2000058511A1 (en) * | 1999-03-26 | 2000-10-05 | Ludwig Institute For Cancer Research | Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3) |
| US20020119921A1 (en) * | 1999-03-31 | 2002-08-29 | Michael Streit | Thrombospondin-2 and uses thereof |
| US6867348B1 (en) * | 1999-12-16 | 2005-03-15 | Xenogen Corporation | Methods and compositions for screening for angiogenesis modulating compounds |
| US20020102260A1 (en) * | 2000-03-02 | 2002-08-01 | Marc Achen | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue |
| EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| AU2001257331A1 (en) | 2000-04-28 | 2001-11-12 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
| ATE306953T1 (de) * | 2001-01-05 | 2005-11-15 | Jacqueline Yvonne Hausdorf | Durch korrosion abbaubare metallische medizinische implantate |
| TWI233361B (en) * | 2001-04-13 | 2005-06-01 | Gen Hospital Corp | Methods of preventing UVB-induced skin damage |
| EP1572902B1 (en) | 2002-02-01 | 2014-06-11 | Life Technologies Corporation | HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES |
| CU23178A1 (es) * | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| WO2003093430A2 (en) | 2002-05-03 | 2003-11-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for use in preparing sirnas |
| WO2004015062A2 (en) | 2002-08-12 | 2004-02-19 | New England Biolabs, Inc. | Methods and compositions relating to gene silencing |
| US20050281761A1 (en) * | 2004-04-01 | 2005-12-22 | Michael Detmar | Methods of preventing UVB-induced skin damage |
-
2007
- 2007-01-18 TW TW096101900A patent/TWI428143B/zh active
- 2007-01-18 EP EP10172193A patent/EP2272497B1/en active Active
- 2007-01-18 JP JP2008551385A patent/JP2009523807A/ja active Pending
- 2007-01-18 ES ES07717966T patent/ES2350269T3/es active Active
- 2007-01-18 ES ES10172193T patent/ES2396440T3/es active Active
- 2007-01-18 CN CN201310303045.1A patent/CN103638522A/zh active Pending
- 2007-01-18 DE DE602007008365T patent/DE602007008365D1/de active Active
- 2007-01-18 KR KR1020087020003A patent/KR20080087164A/ko not_active Ceased
- 2007-01-18 US US11/654,776 patent/US8367609B2/en active Active
- 2007-01-18 KR KR1020157010985A patent/KR101611322B1/ko active Active
- 2007-01-18 WO PCT/US2007/001309 patent/WO2007084599A2/en not_active Ceased
- 2007-01-18 EP EP07717966A patent/EP1984522B1/en active Active
- 2007-01-18 AT AT07717966T patent/ATE476986T1/de not_active IP Right Cessation
- 2007-01-18 CN CNA2007800096055A patent/CN101405408A/zh active Pending
-
2013
- 2013-01-11 US US13/739,533 patent/US9192652B2/en active Active
-
2015
- 2015-05-11 JP JP2015096792A patent/JP2015187119A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015187119A5 (https=) | ||
| Zhang et al. | Microneedle delivery platform integrated with codelivery nanoliposomes for effective and safe androgenetic alopecia treatment | |
| Ben-Mordechai et al. | Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function | |
| BR112013000601A2 (pt) | composições que compreendem um composto de ramificação quase terminal e métodos de produção das mesmas | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
| NO20072802L (no) | Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer | |
| MX360065B (es) | Inhibidores cristalinos de bromodominio. | |
| CO6640250A2 (es) | Formulación tópica que comprende (r)-3-ciclopentil-3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo o una sal farmaceúticamente aceptable del mismo y una emulsión de aceite en agua | |
| MY166050A (en) | Antibody formulation | |
| NO20072804L (no) | Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer | |
| DK1443915T3 (da) | Farmaceutiske og kosmetiske præparater indeholdende aromatiske aldehyder, der bærer en oxygruppe | |
| PE20160878A1 (es) | Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca | |
| JP2015098469A5 (https=) | ||
| JO3122B1 (ar) | مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية | |
| WO2011002179A3 (ko) | 복분자 추출물을 함유하는 피부 주름 개선용 화장료 조성물 | |
| MX2021004296A (es) | Composiciones de conotoxina del antagonista del peptido receptor nicotinico de acetilcolina y metodos relacionados. | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| WO2012161497A3 (ko) | 보습능이 우수한 펩타이드 유도체 및 이의 용도 | |
| JP2012502093A5 (https=) | ||
| WO2011098285A3 (de) | Dermatologische, pharmazeutische zusammensetzung geeignet für oligonukleotide | |
| HK1252057A1 (zh) | 新颖的使用方法和组合物 | |
| WO2012172433A3 (en) | A sustained -release composition containing a melanocortin receptor ligand as the active ingredient | |
| AR087488A1 (es) | Uso de composiciones para retrasar el inicio de la fase catagena del cabello | |
| JP2015511618A5 (https=) |